With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Here's how to get your hands on the hottest clothing, shoes, and accessories launches of 2025, according to our PEOPLE Style ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Nationally-recognized cartoonist Darrin Bell appeared briefly in court Friday afternoon to answer to accusations of ...

A Pulitzer Prize-winning cartoonist was arrested Wednesday and accused of possessing dozens of child sex abuse videos, police said. A search warrant was served Wednesday at the home of Darrin Bell, 49 ...

A Trump-bashing, Pulitzer Prize-winning political cartoonist — whose illustrations have been published by the Washington Post, New Yorker and Los Angeles Times — was arrested for possession of ...

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 million below the low end of the company’s prior guidance and includes $3.5 ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers.

Eli Lilly shares climbed 32% last year but have slumped more than 16% since October after the company reported third quarter sales of the two drugs below Wall Street’s expectations, prompting ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales could portend weaker long-term potential for this market. Lilly is positioned to remain the ...